This website sells research peptides exclusively for scientific and laboratory research purposes.
Do you confirm you are 18+ and accessing this site for legitimate research purposes?
IGF-1 LR3 and IGF-1 DES represent two distinct approaches to IGF-1 analogue research, each with specific pharmacological characteristics. IGF-1 LR3 incorporates an arginine substitution at position 3 and a 13 amino acid N-terminal extension that reduces binding protein affinity, extending the half-life to approximately 20–30 hours compared to native IGF-1. This makes it suitable for research examining sustained systemic anabolic signalling. IGF-1 DES is a truncated form lacking the first three amino acids of IGF-1, which paradoxically increases its potency at the IGF-1 receptor while reducing binding protein affinity. Its shorter half-life and localised activity make it the preferred compound for research examining tissue-specific IGF-1 effects. Published research comparing the two analogues has examined mTOR pathway activation, satellite cell proliferation, glucose uptake and protein synthesis signalling. The choice between systemic (LR3) and localised (DES) IGF-1 signalling research determines which compound is appropriate for a given protocol.
